Drug intelligence / Profile preview

JYS-2

Development stage: Preclinical
Lead developer: Jiuyuan Gene Engineering
Modality: Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

JYS-2 is a biologic drug candidate developed by Hangzhou Jiuyuan Genetic Biopharmaceutical, targeting the glucagon-like peptide-1 (GLP-1) receptor. It is being developed for the treatment of obesity and overweight. Uniquely described in pipeline documents as a polyclonal antibody, JYS-2 aims to leverage the GLP-1 pathway to regulate appetite and glucose metabolism. The drug successfully passed its Investigational New Drug (IND) application in early 2025, positioning it for early-stage clinical development in weight management.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on JYS-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JYS-2.

Explore the full profile